Overview of Dr. Giralt
Dr. Sergio Giralt is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Central University of Venezuela and has been in practice 34 years. Dr. Giralt accepts several types of health insurance, listed below. He is one of 467 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He also speaks multiple languages, including Spanish. He has more than 100 publications and over 500 citings.
Office
Memorial Sloan Kettering Cancer Center New York
1275 York Avenue
New York, NY 10021- Is this information wrong?
Education & Training
- University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1989 - 1993
- TriHealth (Good Samaritan Hospital)Residency, Internal Medicine, 1986 - 1989
- Central University of VenezuelaClass of 1983
Certifications & Licensure
- FL State Medical License 2022 - Present
- NY State Medical License 2010 - 2026
- NJ State Medical License 2021 - 2025
- CT State Medical License 2023 - 2025
- TX State Medical License 1991 - 2025
- OH State Medical License 1989 - 1998
- American Board of Internal Medicine Internal Medicine
Clinical Trials
- Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia Start of enrollment: 1995 Aug 01
- Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Start of enrollment: 1995 Aug 01
- Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia Start of enrollment: 1994 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia.Leland L Metheny, Ronald Sobecks, Christina Cho, Pingfu Fu, Seunghee Margevicius, Jiasheng Wang, Lisa Ciarrone, Shelby Kopp, Robin D Convents, Navneet Majhail, Paolo F...> ;Blood Advances. 2024 Mar 26
- Cell-free DNA from nail clippings as source of normal control for genomic studies in hematologic malignancies.Krystel-Whittemore, M., Petrova-Drus, K., Ptashkin, R., Ewalt, M., Yao, J., Liu, Y., Zhu, M., Benhamida, J., Durham, B., Kumar, J., Nafa, K., Kiecka, I., Bowman, A., G...> ;Haematologica. 2024 Mar 7
- Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens:...Delforge, M., Patel, K., Eliason, L., Dhanda, D., Shi, L., Guo, S., Marshall, T., Arnulf, B., Cavo, M., Nooka, A., Manier, S., Callander, N., Giralt, S., Einsele, H., ...> ;The Lancet. Haematology. 2024 Mar 1
- Join now to see all
Journal Articles
- Strategies to Improve Outcomes of Autologous Hematopoietic Cell Transplant in LymphomaParastoo B Dahi, Hillard M Lazarus, Sergio A Giralt, Craig S Sauter, Nature
- End-of-Life Care for Older AML Patients Relapsing After Allogeneic Stem Cell Transplant at a Dedicated Cancer CenterSergio A Giralt, Virginia M Klimek, Richard J Lin, Ann A Jakubowski, Esperanza B Papadopoulos, Parastoo B Dahi, Nature
Abstracts/Posters
- Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T)Sergio A. Giralt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell LymphomaSergio A Giralt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple My...Sergio Giralt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Approach to the Treatment of the Young, Fit Patient With Myeloma: From Diagnosis to Relapse60th American Society of Hematology Annual Meeting - 12/1/2018
- The Prognostic Calculator Easix Predicts Acute Gvhd, Non-Relapse Mortality and Overall Survival in Adult Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
- Actinium Pharmaceuticals Announces Dr. Sergio Giralt to Discuss Positive Results from the Pivotal Phase 3 SIERRA Trial of Iomab-B via KOL WebinarFebruary 27th, 2023
- Actinium Announces Positive Full Data Results from the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid LeukemiaFebruary 18th, 2023
- Actinium Announces Phase 3 Iomab-B SIERRA Data Accepted for Late-Breaker Presentation at the Transplantation & Cellular Therapy Tandem MeetingsJanuary 12th, 2023
- Join now to see all
Other Languages
- Spanish
Hospital Affiliations
- Memorial Sloan Kettering Cancer CenterNew York, New York
Insurance Accepted
- Aetna Choice POS II
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Choice
GHI PPOGreat West PPO
MVP Healthcare PPO
ODS Network
Oxford Health Freedom
Oxford Health Liberty
PacificSource Preferred PSN
Regence Oregon - Preferred Provider Network
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: